Annual report 2019

Annual report 2019

Celyad Reports Full Year 2019 Financial Results and Provides Business Update

Celyad Reports Full Year 2019 Financial Results and Provides Business Update

Celyad to Announce Full Year 2019 Financial Results and Host Conference Call

Celyad to Announce Full Year 2019 Financial Results and Host Conference Call

Celyad Appoints Stephen Rubino as Chief Business Officer

Celyad Appoints Stephen Rubino as Chief Business Officer

Celyad Announces February and March 2020 Conference Schedule

Celyad Announces February and March 2020 Conference Schedule

Letter to Shareholders - January 2020

Letter to Shareholders - January 2020

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo

Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo

Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablativ e conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients

Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablativ e conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients

Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patien

Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patien

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process